sponsored
PatientsVille.com Logo

PatientsVille

Plavix Medical Research Studies

Up-to-date List of Plavix Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Plavix Medical Research Studies

Rank Status Study
1 Not yet recruiting Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS
Condition: CLOPIDOGREL, POOR METABOLISM of (Disorder)
Interventions: Drug: genotyping guided therapy Ticagrelor, Clopidogrel;   Drug: standard therapy clopidogrel
Outcome Measure: Clopidogrel response status as measured by the LTA assay in CYP2C19*2 carriers.
2 Recruiting Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products
Condition: Antiplatelet Agents
Interventions: Drug: Generic clopidogrel product Apolets®;   Drug: Original clopidogrel product Plavix®
Outcome Measures: Pharmacodynamic effect: The platelet inhibition effect of clopidogrel at the various times on day 7 (0-24 hours) (at steady state);   Pharmacokinetic profiles: Area Under the Concentration-Time Curve (AUC 0-24);   Pharmacokinetic profiles: The Maximum Plasma Concentration (Cmax);   Pharmacokinetic profiles: Time to Maximum Plasma Concentration (Tmax)
3 Recruiting Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
Conditions: Diabetes Type 2;   Diabetic Nephropathy;   Vascular Disease
Interventions: Drug: Ramipril;   Drug: Clopidogrel
Outcome Measures: Changes in Asymmetric dimethylarginine (ADMA) blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Changes in High-sensitivity C-reactive protein (HsCRP) blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Changes in soluble CD40 Ligand (sCD40L)blood levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Changes in urine 8-isoprostane-F2 levels after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Reduction in albumine to creatine ratio after the combined treatment with ramipril and clopidogrel compared with ramipril monotherapy;   Changes in ADMA blood levels after treatment with ramipril;   Increase of Glomerular Filtration Rate (GFR) after combined treatment with ramipril and clopidogrel and after ramipril monotherapy;   Change from baseline in carotid intima-media thickness after combined therapy with ramipril and clopidogrel and after ramipril monotherapy
4 Recruiting Aspirin and Plavix Following Coronary Artery Bypass Grafting
Condition: Coronary Graft Patency
Interventions: Drug: clopidogrel;   Drug: sugar pill
Outcome Measures: Incidence of more than 50% stenosis in graft with combination therapy with aspirin and clopidogrel vs. aspirin alone;   Incidence of bleeding between the two treatment arms;   Percent change major adverse cardiovascular events (angina, any thrombotic events, and myocardial infarction) with combination therapy with aspirin and clopidogrel vs. aspirin alone
5 Not yet recruiting Optimal Anti-platelet Treatment for Patients With Clopidogrel Low Response
Condition: Coronary Artery Disease
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel;   Drug: Cilostazol
Outcome Measures: Inhibition of platelet aggregation (IPA);   Clinical efficacy
6 Recruiting Effectiveness of Clopidogrel Resinate in PCI(PRIDE)
Condition: Coronary Artery Disease
Interventions: Drug: Pregrel®;   Drug: Plavix®
Outcome Measures: composite of death (all cause-mortality), MI (Q wave and non Q wave) and stroke;   composite of death, MI, stroke, or urgent revascularization;   Individual components of death, MI, stroke, or urgent revascularization;   The need for target vessel revascularization or any revascularization;   The incidence of early discontinuation of study drugs;   The incidence of major bleeding events;   Stent thrombosis
7 Not yet recruiting Clopidogrel Resistance and Embolism in Carotid Artery Stenting
Condition: Carotid Stenosis
Interventions: Drug: Ticlopidine + Ginko biloba;   Drug: Clopidogrel
Outcome Measures: New ischemic lesion on diffusion-weighted imaging (DWI);   Number and Volume of new ischemic lesions on DWI;   Benign and malignant microembolic signals (MES) on transcranial Doppler (TCD);   Ischemic stroke or transient ischemic attack (TIA);   Change of clopidogrel resistance;   Pucture site hematoma;   Mycocardial infarction;   Death;   Hematological abnormalities
8 Recruiting Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention
Condition: Acute Coronary Syndrome
Interventions: Drug: Prasugrel;   Drug: Clopidogrel
Outcome Measures: HPR at 24 hours;   MACE;   Bleeding;   HPRs
9 Recruiting Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?
Condition: Clopidogrel
Interventions: Drug: Clopidogrel;   Drug: Discontinue Clopidogrel
Outcome Measures: Perioperative Bleeding Complications;   Development of myocardial infarction or thrombosis
10 Unknown  Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance
Condition: Acute ST SEgment Elevation Myocardial Infarction
Interventions: Drug: Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG;   Drug: Aspirin 100mg and Plavix 75mg
Outcome Measures: To determine usefulness of thromboelastography (TEG) as a valuable tool in assessing platelet response to clopidogrel treatment and post-treatment platelet reactivity during acute ST segment elevation myocardial infarction (STEMI).;   To determine the correlation between platelet response to clopidogrel treatment and the outcome of patients who underwent percutaneous coronary intervention (PCI) for STEMI.
11 Recruiting Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Condition: Coronary Artery Disease
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
Outcome Measures: Compare ticagrelor's versus clopidogrel's inhibition of the P2Y12 receptor as measured by the decrease in P2Y12 Reaction Units (PRU) using VerifyNow TM.;   Compare the decrease of P2Y12 Reaction Units (PRU) by VerifyNow TM from ticagrelor and clopidogrel.;   Compare the decrease in P2Y l2 Reaction Units (PRU) by VerifyNow™ from ticagrelor's and clopidogrel's morning dose on Day 7;   To evaluate and compare the pharmacodynamic effects, measured by the vasodilator-stimulated phosphoprotein (VASP) assay (platelet reactivity index [PRI]), in all subjects;   Assess and to compare the percentage of subjects with High on-treatment Platelet Reactivity (HPR) at all time points after randomized study treatment.
12 Recruiting Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke
Conditions: Brain Ischemia;   Ischemic Attack
Intervention: Drug: Clopidogrel
Outcome Measures: adrenergic component of the platelet response;   VASP-CMF;   ELISA VASP;   active metabolite of clopidogrel;   Genotyping of MDR-1 and P450 2C19
13 Recruiting Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not?
Condition: Acute Coronary Syndrome
Intervention: Drug: Clopidogrel
Outcome Measures: Platelet inhibition as assessed by P2Y12 reaction Unit (PRU) after transition from Ticagrelor to Clopidogrel.;   The difference in platelet inhibition (as expresses as PRU) between the two groups at specified time points.
14 Recruiting Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding
Condition: Gastrointestinal Bleeding
Intervention: Drug: clopidogrel
Outcome Measures: Delayed post-polypectomy bleeding;   Immediate post-polypectomy bleeding
15 Not yet recruiting Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis
Conditions: Acute ST Segment Elevation Myocardial Infarction;   Acute Coronary Syndrome
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
Outcome Measures: Pharmacodynamics (PRU and IPA) of ticagrelor vs Clopidogrel using VASP and VerifyNow;   Pharmacokinetic (AUC, Cmax, Tmax)
16 Unknown  Plavix, Prasugrel and Drug Eluting Stents Pilot Trial
Conditions: Coronary Artery Disease;   Platelet Aggregation Inhibitors;   PCI- Percutaneous Coronary Intervention
Interventions: Drug: Loading Dose Arm;   Drug: Maintenance Dose Arm
Outcome Measures: Change in platelet reactivity after switching medication regimen of two thienopyridines- clopidogrel and prasugrel;   Occurrence of all bleeding events for subjects enrolled into the trial;   Occurrence of all MACE events for subjects enrolled into the trial
17 Unknown  Clopidogrel Reloading in Patients With NSTEACS Undergoing Percutaneous Coronary Intervention on Chronic Clopidogrel Therapy
Conditions: Acute Coronary Syndrome;   Myocardial Infarction
Interventions: Drug: Clopidogrel;   Drug: Placebo
Outcome Measures: Major Adverse Cardiovascular Events;   Bleeding Events;   Grade of platelet residual reactivity
18 Not yet recruiting Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel
Conditions: Diabetes Mellitus;   Coronary Disease
Interventions: Drug: Ticagrelor;   Drug: Continued clopidogrel
Outcome Measures: Rate of elevation of troponin or CK-MB (above the upper limit of normal, and above 3 times the upper limit of normal) measured 20-24 hours after the PCI.;   Rate of major adverse cardiovascular endpoints including death, myocardial infarction or urgent target vessel revascularization at 30 days
19 Recruiting Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
Conditions: Type-2 Diabetes Mellitus;   Coronary Artery Disease
Interventions: Drug: Ticagrelor + Aspirin;   Drug: Clopidogrel + Aspirin
Outcome Measures: Thrombus formation;   Platelet reactivity;   Vasodilator-Stimulated Phosphoprotein phosphorylation assay
20 Unknown  Pharmacogenomics and Effective Treatment With Clopidogrel
Condition: Pharmacogenomics
Intervention: Genetic: Pharmacogenomics
Outcome Measure:

These studies may lead to new treatments and are adding insight into Plavix etiology and treatment.

A major focus of Plavix research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Plavix